Last reviewed · How we verify
Acetaminophen Injectable Product
Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.
Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. Used for Acute pain management, Fever reduction.
At a glance
| Generic name | Acetaminophen Injectable Product |
|---|---|
| Also known as | Tylenol, Paracetamol, Ofirmev |
| Sponsor | Rush University Medical Center |
| Drug class | Analgesic and antipyretic |
| Target | Cyclooxygenase (COX) enzymes |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Acetaminophen works primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production and thereby lowering pain perception and body temperature set point. The intravenous formulation provides rapid systemic delivery for acute pain and fever management in clinical settings where oral administration is not feasible.
Approved indications
- Acute pain management
- Fever reduction
Common side effects
- Hepatotoxicity
- Injection site reactions
- Nausea
- Vomiting
Key clinical trials
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Daratumumab in STK11 Mutated NSCLC (PHASE2)
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients (PHASE4)
- Optimizing Pain Treatment in Children On Mechanical Ventilation (PHASE3)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Opioid-Sparing Joint Replacement (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetaminophen Injectable Product CI brief — competitive landscape report
- Acetaminophen Injectable Product updates RSS · CI watch RSS
- Rush University Medical Center portfolio CI